Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Trial Of Fulvestrant (Faslodex (Registered)). With Or Without Pd-0332991 (Palbociclib) +/- Goserelin In Women With Hormone Receptor-positive, Her2-negative Metastatic Breast Cancer Whose Disease Progressed After Prior Endocrine Therapy

Trial Profile

Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Trial Of Fulvestrant (Faslodex (Registered)). With Or Without Pd-0332991 (Palbociclib) +/- Goserelin In Women With Hormone Receptor-positive, Her2-negative Metastatic Breast Cancer Whose Disease Progressed After Prior Endocrine Therapy

Discontinued
Phase of Trial: Phase III

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Palbociclib (Primary) ; Fulvestrant; Goserelin
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms PALOMA-3
  • Sponsors Pfizer
  • Most Recent Events

    • 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jun 2017 Planned locations also included France, Mexico, South Africa, South Korea, Switzerland as per European Clinical Trials Database.
    • 02 Jun 2017 Results of exposure-response analyses for efficacy and safety endpoints, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top